🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

18 results for “Avalo” Clear

  1. NFC-1

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  2. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule and tablet, Normal Saline, Prednisolon STADA® 10 mg Tabletten, [1-13C]SODIUM ACETATE, Avalotcagene ontaparvovec

    Pharma Mar S.A.

    Late-onset Ornithine transcarbamylase (OTC) deficiency

    phase 3 small molecule active

    1 trial

  3. AEVI-001

    Avalo Therapeutics

    Attention Deficit Hyperactivity Disorder

    phase 2 small molecule completed

    2 trials

  4. AVTX-002

    Avalo Therapeutics

    Non-Eosinophilic Asthma

    phase 2 small molecule completed

    1 trial

  5. AVTX-009 Regimen 1

    Avalo Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  6. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial

  7. CERC-301

    Avalo Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    2 trials

  8. FP01

    Avalo Therapeutics

    Acute Cough

    phase 2 small molecule completed

    1 trial

  9. FP01

    Avalo Therapeutics

    Chronic Refractory Cough

    phase 2 small molecule completed

    1 trial

  10. MDGN201 TARGTEPO

    Avalo Therapeutics

    Anemia of End Stage Renal Disease

    phase 2 mab terminated

    1 trial

  11. Placebo to AVTX-009, AVTX-009

    Avalo Therapeutics

    Hidradenitis suppurativa (HS)

    phase 2 small molecule active

    1 trial

  12. AEVI-007

    Avalo Therapeutics

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  13. CERC-006

    Avalo Therapeutics

    Lymphatic Malformation

    phase 1 small molecule terminated

    1 trial

  14. FP01

    Avalo Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  15. MDGN-002

    Avalo Therapeutics

    Crohn Disease

    phase 1 small molecule terminated

    1 trial

  16. NFC-1

    Avalo Therapeutics

    Attention-deficit Hyperactivity Disorder (ADHD)

    phase 1 small molecule completed

    1 trial

  17. NFC-1

    Avalo Therapeutics

    22q11.2 Deletion Syndrome

    phase 1 small molecule completed

    1 trial

  18. NFC-1 100 mg

    Avalo Therapeutics

    Attention Deficit Disorder With Hyperactivity

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources